Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase I trial studies the side effects of Nozin in preventing respiratory viral infections in patients undergoing stem cell transplant. Nozin is a non-antibiotic, alcohol-based nasal sanitizer used in hospitals to prevent spread of bacterial infections and may also prevent community acquired respiratory virus infection in stem cell transplant recipients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fred Hutchinson Cancer Research Center
• Collaborators: Global Life Technologies Corp.; National Cancer Institute (NCI)
• Treatments: Ethanol; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Undergoing allogeneic hematopoietic transplant for malignant or non-malignant disease

• English speaking

• Capable of providing informed consent

• Planned to receive follow-up at the transplant site for the first 100 days post transplantation

• Subjects who the investigator believes can and will comply with the study protocol

Exclusion Criteria:

• Documented respiratory viral infection in the two weeks prior to enrollment

• Current or planned use of any prophylactic antiviral therapy, antibody treatments, or other agents targeting the prevention of respiratory viruses (i.e. oseltamivir, ribavirin, amantadine)

• Known allergy to study drug components (jojoba, orange oil, coconut oil, lauric acid, benzalkonium chloride, vitamin E)

• Receiving oxygen supplementation at time of enrollment

• Active mucositis at time of enrollment

• Ongoing irritation or active infection of the squamous epithelial cell skin involving the nose or nasal vestibule

• Daily use of nasal decontamination products or other nasal medications (e.g. nasal steroids)

• Unable to complete study procedures (e.g. nasal swab self-testing)